Which has better valuation and earnings, IVA or RLAY?

Relay Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 206.64 -$400.67M N/A N/A Relay Therapeutics $10.68M 330.91 -$276.48M -$1.57 N/A

Is IVA or RLAY more profitable?

Inventiva's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Relay Therapeutics N/A -43.94% -40.11%

Does the media refer more to IVA or RLAY?

In the previous week, Relay Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.53 beat Relay Therapeutics' score of 0.39 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, IVA or GPCR?

Structure Therapeutics has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 206.64 -$400.67M N/A N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is IVA or GPCR more profitable?

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Structure Therapeutics N/A -24.91% -23.67%

Does the media prefer IVA or GPCR?

In the previous week, Structure Therapeutics had 6 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for Structure Therapeutics and 3 mentions for Inventiva. Structure Therapeutics' average media sentiment score of 1.03 beat Inventiva's score of 0.53 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IVA or DNLI?

Inventiva has higher earnings, but lower revenue than Denali Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 206.64 -$400.67M N/A N/A Denali Therapeutics $330.53M 11.10 -$512.54M -$2.88 N/A

Is IVA or DNLI more profitable?

Inventiva's return on equity of 0.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Denali Therapeutics N/A -52.20% -43.86%

Does the media prefer IVA or DNLI?

In the previous week, Denali Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Denali Therapeutics and 3 mentions for Inventiva. Denali Therapeutics' average media sentiment score of 0.71 beat Inventiva's score of 0.53 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, RCUS or IVA?

Arcus Biosciences has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcus Biosciences $236M 15.14 -$353M -$3.18 N/A Inventiva $4.48M 206.64 -$400.67M N/A N/A

Does the media refer more to RCUS or IVA?

In the previous week, Arcus Biosciences had 13 more articles in the media than Inventiva. MarketBeat recorded 16 mentions for Arcus Biosciences and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.53 beat Arcus Biosciences' score of 0.38 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, IVA or OGN?

Organon & Co. has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 206.64 -$400.67M N/A N/A Organon & Co. $6.16B 0.58 $187M $0.93 14.54

Does the media prefer IVA or OGN?

In the previous week, Inventiva and Inventiva both had 3 articles in the media. Inventiva's average media sentiment score of 0.53 beat Organon & Co.'s score of 0.48 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Inventiva (IVA) Competitors

$4.46 -0.05 (-1.11%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.46 +0.00 (+0.11%)

As of 07/24/2026 04:10 PM Eastern

Compare

IVA vs. RLAY, GPCR, DNLI, RCUS, and OGN

Should you buy Inventiva stock or one of its competitors? MarketBeat compares Inventiva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inventiva include Relay Therapeutics (RLAY), Structure Therapeutics (GPCR), Denali Therapeutics (DNLI), Arcus Biosciences (RCUS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.

How does Inventiva compare to Relay Therapeutics?

Inventiva (NASDAQ:IVA) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Inventiva's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Relay Therapeutics	N/A	-43.94%	-40.11%

Relay Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A
Relay Therapeutics	$10.68M	330.91	-$276.48M	-$1.57	N/A

Inventiva has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 271.20%. Relay Therapeutics has a consensus target price of $24.92, suggesting a potential upside of 35.12%. Given Inventiva's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inventiva is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Relay Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.53 beat Relay Therapeutics' score of 0.39 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Inventiva and Relay Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Inventiva compare to Structure Therapeutics?

Inventiva (NASDAQ:IVA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Structure Therapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Structure Therapeutics	N/A	-24.91%	-23.67%

Inventiva has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market.

In the previous week, Structure Therapeutics had 6 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for Structure Therapeutics and 3 mentions for Inventiva. Structure Therapeutics' average media sentiment score of 1.03 beat Inventiva's score of 0.53 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 271.20%. Structure Therapeutics has a consensus target price of $110.55, suggesting a potential upside of 125.05%. Given Inventiva's stronger consensus rating and higher possible upside, equities analysts clearly believe Inventiva is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Inventiva beats Structure Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Inventiva compare to Denali Therapeutics?

Inventiva (NASDAQ:IVA) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Denali Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Denali Therapeutics and 3 mentions for Inventiva. Denali Therapeutics' average media sentiment score of 0.71 beat Inventiva's score of 0.53 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 271.20%. Denali Therapeutics has a consensus target price of $35.17, suggesting a potential upside of 52.17%. Given Inventiva's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inventiva is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Inventiva has higher earnings, but lower revenue than Denali Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A
Denali Therapeutics	$330.53M	11.10	-$512.54M	-$2.88	N/A

Inventiva's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Denali Therapeutics	N/A	-52.20%	-43.86%

19.1% of Inventiva shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Inventiva beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Inventiva compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arcus Biosciences currently has a consensus target price of $36.40, indicating a potential upside of 28.12%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 271.20%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Arcus Biosciences has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	15.14	-$353M	-$3.18	N/A
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A

Inventiva has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Inventiva's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Inventiva	N/A	N/A	N/A

Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

In the previous week, Arcus Biosciences had 13 more articles in the media than Inventiva. MarketBeat recorded 16 mentions for Arcus Biosciences and 3 mentions for Inventiva. Inventiva's average media sentiment score of 0.53 beat Arcus Biosciences' score of 0.38 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inventiva beats Arcus Biosciences on 9 of the 15 factors compared between the two stocks.

How does Inventiva compare to Organon & Co.?

Inventiva (NASDAQ:IVA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Inventiva and Inventiva both had 3 articles in the media. Inventiva's average media sentiment score of 0.53 beat Organon & Co.'s score of 0.48 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 271.20%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.71%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts clearly believe Inventiva is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Inventiva has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	206.64	-$400.67M	N/A	N/A
Organon & Co.	$6.16B	0.58	$187M	$0.93	14.54

19.1% of Inventiva shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. has a net margin of 3.99% compared to Inventiva's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Organon & Co.	3.99%	99.95%	6.22%

Summary

Inventiva and Organon & Co. tied by winning 7 of the 14 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$936.76M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	N/A	21.11	27.00	23.71
Price / Sales	206.64	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-20.27	7.88	10.28	6.07
Net Income	-$400.67M	$23.81M	$3.60B	$331.99M
7 Day Performance	-3.46%	-3.82%	-1.29%	-0.61%
1 Month Performance	27.43%	-2.61%	-0.38%	-1.98%
1 Year Performance	42.31%	32.79%	18.32%	13.67%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.3468 of 5 stars	$4.46 -1.1%	$16.56 +271.2%	+35.8%	$936.76M	$4.48M	N/A	100
RLAY Relay Therapeutics	2.9573 of 5 stars	$18.93 +1.1%	$23.73 +25.3%	+401.1%	$3.63B	$15.35M	N/A	330	News Coverage Analyst Forecast
GPCR Structure Therapeutics	2.2995 of 5 stars	$50.99 -1.3%	$110.55 +116.8%	+168.9%	$3.62B	N/A	N/A	136	News Coverage Positive News
DNLI Denali Therapeutics	2.6065 of 5 stars	$22.69 -14.3%	$34.75 +53.2%	+61.5%	$3.61B	$330.53M	N/A	430	News Coverage Analyst Forecast
RCUS Arcus Biosciences	3.0622 of 5 stars	$28.30 +0.8%	$35.10 +24.0%	+187.7%	$3.55B	$247M	N/A	500	News Coverage Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. RLAY, GPCR, DNLI, RCUS, and OGN

How does Inventiva compare to Relay Therapeutics?

Summary

How does Inventiva compare to Structure Therapeutics?

Summary

How does Inventiva compare to Denali Therapeutics?

Summary

How does Inventiva compare to Arcus Biosciences?

Summary

How does Inventiva compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. RLAY, GPCR, DNLI, RCUS, and OGN

How does Inventiva compare to Relay Therapeutics?

Is IVA or RLAY more profitable?

Which has better valuation and earnings, IVA or RLAY?

Which has more volatility & risk, IVA or RLAY?

Do analysts prefer IVA or RLAY?

Does the media refer more to IVA or RLAY?

Do institutionals & insiders have more ownership in IVA or RLAY?

Summary

How does Inventiva compare to Structure Therapeutics?

Do insiders and institutionals hold more shares of IVA or GPCR?

Which has stronger valuation and earnings, IVA or GPCR?

Is IVA or GPCR more profitable?

Which has more risk and volatility, IVA or GPCR?

Does the media prefer IVA or GPCR?

Do analysts recommend IVA or GPCR?

Summary

How does Inventiva compare to Denali Therapeutics?

Does the media prefer IVA or DNLI?

Which has more volatility and risk, IVA or DNLI?

Do analysts rate IVA or DNLI?

Which has better valuation and earnings, IVA or DNLI?

Is IVA or DNLI more profitable?

Do institutionals and insiders have more ownership in IVA or DNLI?

Summary

How does Inventiva compare to Arcus Biosciences?

Do institutionals & insiders have more ownership in RCUS or IVA?

Do analysts rate RCUS or IVA?

Which has better earnings & valuation, RCUS or IVA?

Is RCUS or IVA more profitable?

Which has more risk & volatility, RCUS or IVA?

Does the media refer more to RCUS or IVA?

Summary

How does Inventiva compare to Organon & Co.?

Does the media prefer IVA or OGN?

Do analysts prefer IVA or OGN?

Which has more volatility & risk, IVA or OGN?

Which has stronger earnings & valuation, IVA or OGN?

Do insiders and institutionals have more ownership in IVA or OGN?

Is IVA or OGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools